|Articles|March 1, 2003

What goes down doesn't all come up

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Atopic dermatitis linked to higher ADHD risk in children, with sleep disturbance emerging as key factor | Image Credit: © triocean - stock.adobe.com.

Atopic dermatitis linked to higher ADHD risk in children, with sleep disturbance emerging as key factor

ByMorgan Ebert, Executive Editor

September 15th 2026

Disease severity, phenotype predict systemic treatment response in pediatric alopecia areata | Image Credit: © geargodz - stock.adobe.com.

Disease severity, phenotype predict systemic treatment response in pediatric alopecia areata

ByMorgan Ebert, Executive Editor

September 15th 2026

Teen sports supplements: What to recommend, use with caution, and avoid

Teen sports supplements: What to recommend, use with caution, and avoid

ByColleen Sloan, PA-C, RDN

September 14th 2026

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial | Image Credit: © Yurii Kibalnik - stock.adobe.com

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial

ByMorgan Ebert, Executive Editor

September 14th 2026

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

ByMorgan Ebert, Executive Editor

September 14th 2026

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

Teen sports supplements: What to recommend, use with caution, and avoid

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial

Disease severity, phenotype predict systemic treatment response in pediatric alopecia areata

How Breast Milk Shapes Gut Microbiome Signaling and Immunity